肥胖和心力衰竭-GLP-1受体激动剂的作用
Gregor Simonis1, Ulrike Schatz2
1Kardiologische Ambulanz und Herzkatheterlabor, MVZ Praxisklinik Herz und Gefäße, Forststraße 3, 01099, Dresden, Germany. gregor.simonis@praxisklinik-dresden.de.
Herz
|April 2, 2025
概括
葡萄糖类-1 (GLP-1) 受体激活剂和蒂尔泽帕提德在治疗肥胖引起的心力衰竭中表现出有前途的效果,使用保存的喷射分数 (HFpEF). 这些疗法可以改善HFpEF患者的症状和结果,无论糖尿病状况如何.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖是心力衰竭的重要驱动因素,引起各种病理生理变化.
- 标准治疗,如利尿剂,SGLT2抑制剂和矿物质皮质抗剂,可能无法完全缓解这些患者的症状.
- 了解新的治疗目标对于改善HFpEF管理至关重要.
研究的目的:
- 审查目前关于GLP-1受体激动剂和tirezepatide在肥胖驱动的HFpEF中的证据.
- 评估这些药物在改善症状和临床结果方面的疗效.
- 评估它们在患有和没有糖尿病的患者中的有用性.
主要方法:
- 临床研究和试验的文献综述.
- 分析有关患者症状和不良事件的数据.
- 在肥胖和糖尿病的背景下检查与HFpEF相关的结果.
主要成果:
- GLP-1受体激动剂和蒂尔泽帕提德在控制由肥胖驱动的HFpEF症状方面显示出潜在的益处.
- 这些药物可能会在受影响的患者群体中改善心血管结果.
- 证据表明,无论伴随性糖尿病状况如何,疗效是可以的.
结论:
- GLP-1受体激动剂和蒂尔泽帕提德代表了与肥胖相关的HFpEF的有希望的治疗途径.
- 需要进一步的研究来充分阐明它们的长期益处和最佳使用.
- 这些药物可以成为对肥胖个体HFpEF治疗的有价值的补充.
相关概念视频
Glucagon-like Receptor Agonists
272
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
272
Oral Hypoglycemic Agents: Biguanides and Glitazones
143
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
143
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
128
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
128
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
G Protein-coupled Receptors
10.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
10.9K
Dipeptidyl Peptidase 4 Inhibitors
140
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
140


